cck

CCK-A receptor inhibitor 1 is a potent cholecystokinin A (CCK-A) receptor inhibitor (IC50: 340 nM) and can be used to study digestive system-related diseases.

CCK Octapeptide, non-sulfated acetate is a synthetic desulfated peptide of cholecystokinin.

GV-150013X ((S)-1-(1-(adamantan-1-ylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-3-phenylurea) is a potent CCKB antiagonist, pKi= 9.02.

Pranazepide (FK 480) is a small molecule cholecystokinin receptor antagonist used to study digestive disorders and pancreatitis.

Spiroglumide, a CCKB-gastrin antagonist that inhibits dose-dependent pentagastrin-induced acid hypersecretion with an ID50 of 20.1 (8.67-46.4) mg / kg, could be used to explore the physiological role of gastrin in the regulation of human gastric acid secretion.

Lorglumide sodium salt (CR-1409 sodium salt) is an antagonist of cholecystokinin receptors (CCK).

Ceruletide Ammonium acetate (FI-6934 Ammonium acetate) is a cholecystokinin (CCK) receptor agonist. Ceruletide Ammonium acetate is a safe and effective cholecystokinetic agent and small bowel and exocrine pancreatic stimulant.

Sincalide (CCK-8) is a cholecystokinetic drug administered by injection to aid in diagnosing disorders of the gallbladder and pancreas. It is the 8-amino acid C-terminal fragment of cholecystokinin.

Sincalide ammonium (CCK-8 ammonium) is a potent analog of the amino acid peptide hormone cholecystokinin (CCK), an active fragment that retains much of the biological activity of CCK.Sincalide ammonium promotes bile secretion, causes gallbladder contractions and relaxes the sphincter of Oddi, thereby facilitating bile drainage into the duodenum. Sincalide ammonium promotes bile secretion, contraction of the gallbladder and relaxation of the sphincter of Oddi, thereby facilitating the drainage of bile into the duodenum.Sincalide ammonium can be injected to promote gallbladder contraction, and is commonly used as an adjunct in the diagnosis of gallbladder and pancreatic diseases and in cholecystography.

Gastrin CCK antagonist 1 is a potent gastrin CCK antagonist for the study of metabolic system-related diseases.

CCK-B Receptor Antagonist 2 is a potent and orally active antagonist of Gastrin CCK-B (IC50: 0.43 nM). It also inhibits gastrin CCK-A activity (IC50: 1.82 μM).

CCK-B Receptor Antagonist 1 is a cholecystokinin B (CCK-B) receptor agonist and has the potential of reducing the secretion of gastric acid.

CCK (26-30) is an N-terminal fragment of CCK , a peptide hormone found in the intestine and brain that stimulates digestion, mediates satiety, and is involved in anxiety. The sulfated form of CCK (26-30) inhibits binding of [125I]CCK-33 to guinea pig cortical membranes by 10% when used at a concentration of 0.1 mM.

CCK (26-31) is an N-terminal fragment of CCK , a peptide hormone found in the intestine and brain that stimulates digestion, mediates satiety, and is involved in anxiety.

CCK (26-31) is an N-terminal fragment of CCK , a peptide hormone found in the intestine and brain that stimulates digestion, mediates satiety, and is involved in anxiety. The sulfated form of CCK (26-31) inhibits binding of [125I]CCK-33 to guinea pig cortical membranes by 21% when used at a concentration of 0.1 mM.

CCK (27-33) is a C-terminal fragment of CCK , a peptide hormone found in the intestine and brain that stimulates digestion, mediates satiety, and is involved in anxiety. Non-sulfated CCK (27-33) inhibits binding of [3H]naloxone in rat cerebellum membranes (IC50 = 4 uM) and inhibits electrically-stimulated contraction of isolated guinea pig ileum (IC50 = 17 uM), an effect that can be reversed by naloxone. Unlike sulfated CCK (27-33), the non-sulfated form does not reduce exploratory behavior in mice when administered at doses up to 1 uMol/kg.

CCK2R Ligand-Linker Conjugate 1 is a hydrophilic peptide linker that conjugates to the cytotoxic antimicrotubule agents Desacetyl Vinblastine Hydrazide (DAVBH) and Tubulysin B Hydrazide (TubBH) as ligand-linker conjugates[1].

Creatine kinase (OcCK) catalyzes the reversible reaction of creatine and ATP to form phosphocreatine and ADP. Creatine kinase (OcCK) is a key enzyme for maintaining a constant ATP ADP ratio during rapid energy turnover [1] .

DSPE-PEG2000-CCK8 is a PEG compound comprising DSPE and Cholecystokinin-8 (CCK8). Cholecystokinin-8 exhibits peptide activity responsible for regulating gallbladder contractions and digestive system functions. DSPE-PEG2000-CCK8 is applicable for drug delivery.

DSPE-PEG1000-CCK8 is a PEG compound composed of DSPE and Cholecystokinin-8 (CCK8). Cholecystokinin-8 exhibits peptide activity that regulates gallbladder contraction and the functions of the digestive system. DSPE-PEG1000-CCK8 can be utilized for drug delivery.

DSPE-PEG5000-CCK8 is a PEGylated compound comprised of DSPE and Cholecystokinin-8 (CCK8). Cholecystokinin-8 exhibits peptide activity that regulates gallbladder contraction and the functioning of the digestive system. DSPE-PEG5000-CCK8 can be applied in drug delivery systems.

Ceruletide is a decapeptide that serves as a safe and effective cholecystokinin receptor agonist, exerting a direct spasmogenic effect on the gallbladder muscle and bile ducts, and is commonly used to establish pancreatitis models.

(Iso)-FK-480 is a novel orally available cholecystokinin A (CCK-A) antagonist for investigational treatment of chronic pancreatitis.

A-65186 is an A-type glutamatergic cholecystokinin (CCK) antagonist used to study inflammation and gastrointestinal tract injury.